脑脊液动力学障碍:与阿尔茨海默生物标志物及认知的关系
本研究基于Mayo Clinic衰老研究队列的684名≥50岁参与者,采用自动化机器学习算法检测高凸面紧贴脑沟(HCTS),并分析其与淀粉样蛋白PET、tau PET及认知状态的关系。结果显示HCTS占6.6%,与年龄增长、认知障碍比例更高相关,且HCTS患者tau SUVR更低但AD特征皮层厚度更薄,在A/T/N框架中富集于T-(N)+组。结论认为HCTS代表一种非AD病理生理亚组,可能与认知障碍相关并混淆AD临床试验解读。
要点
- HCTS在人群中的频率为6.6%,与年龄增长和认知障碍比例升高相关。
- HCTS患者tau SUVR更低但AD特征皮层厚度更薄,提示非AD病理。
- HCTS在A/T/N框架中富集于T-(N)+组,可能混淆AD临床试验解读。
核心结论
- HCTS代表一种可定义的非AD病理生理亚组(即T-[N]+),与认知障碍相关。
- HCTS可能混淆AD临床试验中的临床和生物标志物解读。
研究设计与样本
- 研究分析了684名≥50岁、来自前瞻性人群为基础的Mayo Clinic衰老研究的参与者。
- 所有参与者接受了结构MRI、淀粉样蛋白PET和tau PET成像。
- 使用先前内部开发的全自动机器学习算法检测HCTS的神经影像特征。
- 根据PET和MRI指标将参与者分类为淀粉样蛋白正常(A-)或异常(A+)、tau正常(T-)或异常(T+)、神经变性正常(N-)或异常(N+)。
- 神经心理测验评估了领域特异性和全局认知评分,并评估了步速;分析均校正了年龄和性别。
主要发现
- 684名参与者中,45名(6.6%)根据自动化算法被分类为HCTS。
- HCTS患者年龄大于无HCTS者(平均[SD] 78.0[8.3] vs 71.9[10.8]岁;p < 0.001)。
- 经年龄和性别校正后,HCTS患者认知障碍比例更高(27% vs 9%;p = 0.005)。
- HCTS患者与无HCTS者的淀粉样蛋白PET状态相似,但经年龄和性别校正后HCTS患者tau PET标准摄取值比率(SUVR)更低(p < 0.001)。
- 尽管tau SUVR更低,HCTS患者的AD特征皮层厚度更薄;在A/T/N框架中,无论淀粉样蛋白状态如何,HCTS在T-(N)+组中过度代表。
临床怎么用
- 临床解读AD生物标志物时需注意HCTS可能造成的混淆,尤其是在T-(N)+组中。
- 对于存在HCTS的认知障碍患者,应考虑非AD病理生理机制的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the frequency of high-convexity tight sulci (HCTS) in a population-based sample and whether the presence of HCTS and related features influenced participants' cognitive status and classification within the new Alzheimer-biomarker framework. METHODS: We analyzed 684 participants ≥50 years of age who were enrolled in the prospective population-based Mayo Clinic Study of Aging and underwent structural MRI, amyloid PET imaging, and tau PET imaging. A fully automated machine-learning algorithm that had been developed previously in house was used to detect neuroimaging features of HCTS. On the basis of PET and MRI measures, participants were classified as having normal (A-) or abnormal (A+) amyloid, normal (T-) or abnormal (T+) tau, and normal (N-) or abnormal (N+) neurodegeneration. The neuropsychological battery assessed domain-specific and global cognitive scores. Gait speed also was assessed. Analyses were adjusted for age and sex. RESULTS: Of 684 participants, 45 (6.6%) were classified with HCTS according to the automated algorithm. Patients with HCTS were older than patients without HCTS (mean [SD] 78.0 [8.3] vs 71.9 [10.8] years; p < 0.001). More were cognitively impaired after age and sex adjustment (27% vs 9%; p = 0.005). Amyloid PET status was similar with and without HCTS, but tau PET standard uptake value ratio (SUVR) was lower for those with HCTS after age and sex adjustment (p < 0.001). Despite a lower tau SUVR, patients with HCTS had lower Alzheimer disease (AD) signature cortical thickness. With the amyloid-tau-neurodegeneration framework, HCTS was overrepresented in the T-(N)+ group, regardless of amyloid status. CONCLUSION: The HCTS pattern represents a definable subgroup of non-AD pathophysiology (i.e., T-[N]+) that is associated with cognitive impairment. HCTS may confound clinical and biomarker interpretation in AD clinical trials.
引用
- Graff-Radford J, Gunter JL, Jones DT, et al. Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition. Neurology. 2019. PMID: 31719134. doi:10.1212/WNL.0000000000008616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。